These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35347027)

  • 1. Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer.
    Fujiwara M; Fujiwara R; Urasaki T; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T
    Anticancer Res; 2022 Apr; 42(4):2045-2051. PubMed ID: 35347027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
    Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
    Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
    Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
    In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
    Yamamoto Y; Yatsuda J; Shimokawa M; Fuji N; Aoki A; Sakano S; Yamamoto M; Suga A; Tei Y; Yoshihiro S; Kitahara S; Nagao K; Takai K; Kamiryo Y; Akao J; Yamaguchi S; Oba K; Shimabukuro T; Matsumoto H; Kamba T; Matsuyama H
    Int J Clin Oncol; 2021 Jan; 26(1):169-177. PubMed ID: 32948925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.
    Kadono Y; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kamijima T; Seto C; Takano A; Yotsuyanagi S; Nakagawa R; Miyagi T; Aoyama S; Asahi H; Fukuda R; Mizokami A
    Anticancer Res; 2021 Mar; 41(3):1599-1606. PubMed ID: 33788755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
    Kobayashi T; Ito K; Kojima T; Maruyama S; Mukai S; Tsutsumi M; Miki J; Okuno T; Yoshio Y; Matsumoto H; Shimazui T; Segawa T; Karashima T; Masui K; Fukuta F; Tashiro K; Imai K; Suekane S; Nagasawa S; Higashi S; Fukui T; Ogawa O; Kitamura H; Nishiyama H
    Cancer Immunol Immunother; 2022 Feb; 71(2):461-471. PubMed ID: 34235546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
    Uchimoto T; Nakamura K; Komura K; Fukuokaya W; Yano Y; Nishimura K; Kinoshita S; Nishio K; Fukushima T; Nakamori K; Matsunaga T; Tsutsumi T; Tsujino T; Taniguchi K; Tanaka T; Uehara H; Takahara K; Inamoto T; Kimura T; Egawa S; Azuma H
    Urol Oncol; 2022 Jul; 40(7):344.e11-344.e17. PubMed ID: 35346572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
    Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
    Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
    Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
    Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.
    Yanagisawa T; Mori K; Katayama S; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Motlagh RS; Aydh A; König F; Grossmann NC; Pradere B; Miki J; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2022 Jan; 27(1):59-71. PubMed ID: 34757531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab.
    Umeda K; Tanaka N; Yasumizu Y; Takeda T; Matsumoto K; Morita S; Kosaka T; Mizuno R; Oya M
    Clin Genitourin Cancer; 2023 Feb; 21(1):128-135. PubMed ID: 36058808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
    Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
    Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.
    Nishio K; Higashio T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Tsuchida S; Matsuda T; Tsujino T; Nishimura K; Tokushige S; Nakamori K; Uchimoto T; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Kimura T; Ohno Y; Shiroki R; Azuma H
    Oncology; 2024; 102(6):457-464. PubMed ID: 37839399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study.
    Qiang H; Lei Y; Shen Y; Li J; Zhong H; Zhong R; Zhang X; Chang Q; Lu J; Feng H; Zhu Y; Addeo A; Banna GL; Oh IJ; Qian J; Chu T
    Transl Lung Cancer Res; 2022 Jan; 11(1):87-99. PubMed ID: 35242630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma.
    Fukata S; Mizutani K; Yamamoto S; Kuno T; Fukuhara H; Ashida S; Karashima T; Inoue K
    Anticancer Drugs; 2022 Jun; 33(5):459-466. PubMed ID: 35417424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma.
    Miyama Y; Kaneko G; Nishimoto K; Yasuda M
    Cancer Med; 2022 Nov; 11(22):4236-4245. PubMed ID: 35699000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
    Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.